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1,3-Butadiene (CHZCH-CH=CH2), a high-volume,
colorless gas, used mainly in the production ofsynthetic
rubber, has long been considered to have low and non-
cumulative toxicologic potential in animals and humans.
In fact, the current standard of1000 ppm, promulgated
by the Occupational Safety and Health Administration
(OSHA) as an 8-hr, time-weighted average (TWA)
workroom exposure concentration, was aimed at pre-
ventingirritationtothe eyesand upperrespiratorytract
of exposed workers. However, results oflong-term in-
halation studies conducted by the National Toxicology
Programand bythe International Institute ofSynthetic
Rubber Producers showed that 1,3-butadiene is carci-
nogenic in mice and rats. These findings raised greater
concerns of potential risk for humans exposed to this
chemical. In 1984, the American Conference ofGovern-
mental Industrial Hygienists reduced their recom-
mended threshold limit value-TWA for 1,3-butadiene
from 1000 to 10 ppm. In February 1984, the National
Institute for Occupational Safety and Health (NIOSH)
issued a hazard alert indicating that 1,3-butadiene
should be regarded as a potential occupational carcino-
gen (Current Intelligence Bulletin 41). OSHA is evalu-
ating the current workplace standard for this chemical.
Toprovide an openforumtoevaluatethecurrentstate
of knowledge on the toxicology, carcinogenesis, and
human health aspects of 1,3-butadiene and to discuss
ongoing studies orthose beingplanned, aninternational
symposium on 1,3-butadiene was held at the National
Institute ofEnvironmental Health Sciences in Research
Triangle Park, North Carolina, onApril 12and 13, 1988.
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Scientists from government, industry, and academia,
who are actively examining various health-related as-
pects of1,3-butadiene, presented results oftheirnew or
updated studies and participated in general discussions
aimed at furthering our understanding ofthe scientific
facts, and the key issues that will have an impact on
regulatory decisions aimed at protecting the health of
the public and ofworkers occupationally exposed to 1,3-
butadiene.
This meeting was sponsored by government, indus-
try, and union groups: the National Institute of Envi-
ronmental Health Sciences (NIEHS), the International
Institute of Synthetic Rubber Producers (IISRP),
the National Institute for Occupational Safety and
Health (NIOSH), the Occupational Safety and Health
Administration (OSHA), the Environmental Protection
Agency (EPA), the Industrial Union Department
(IUD), and the Chemical Manufacturers Association
(CMA). Approximately 120 people participated in the
meeting, with participants from Canada, Federal Re-
public of Germany, Great Britain, Italy, Mexico,
Netherlands, and the United States.
The two-day symposium was divided into seven ses-
sions: 1) "Industrial use and occupational exposure to
1,3-butadiene," chaired by L. Beliczky, United Rubber
Workers Union, Akron, OH;2)"Carcinogenicitystudies
of 1,3-butadiene in rats and mice," chaired by J. Huff,
NIEHS, Research Triangle Park, NC; 3) "Mechanistic
andpharmacokineticstudies of1,3-butadieneinratsand
mice," chairedbyM. Wooder, ShellInternationalPetro-
leum, The Hague, Netherlands; 4) "Genetic and devel-
opmental toxicology studies of 1,3-butadiene," chaired
byE. Loeser, BayerAG, WestGermany; 5)"Toxicology
studies of isoprene (2-methyl-1,3-butadiene)," chaired
byR. Scala, ExxonBiomedicalSciences, EastMillstone,
NJ; 6) "Epidemiology studies of1,3-butadiene," chaired
by D. Hoel, NIEHS, Research Triangle Park, NC; and
7) "Risk assessment of 1,3-butadiene," chaired byJ. D.
Millar, NIOSH, Centers for Disease Control, Atlanta,MELNICK ET AL.
GA. A briefsummary and overview ofthe dataand key
findings presented at the symposium are given below.
More details and extended discussions can be obtained
from the following 25 individual papers that comprise
these proceedings.
The annual production of 1,3-butadiene is about 3
billionpoundsintheUnited Statesandapproximately 12
billionpounds worldwide (N. L. Morrow, ExxonChemi-
cal Co.). Annualatmospheric emissions of1,3-butadiene
from production or polymer manufacturing plants is
approximately 10 million pounds, most of which is at-
tributable to equipment leaks (J. A. Mullins, Shell Oil
Co.). Occupational exposure to 1,3-butadiene in mono-
merproduction orfrompolymermanufacturingplantsis
generally less than 20 ppm; however, excursions in
certain jobs resulted in exposures as high as 375 ppm
(J. M. Fajen, NIOSH).
In laboratory animal studies, 1,3-butadiene produced
neoplasms at multiple organ sites in Sprague-Dawley
rats (pancreas, uterus, Zymbal gland, mammary gland,
thyroid, and testis) (P. E. Owen, Hazleton, UK) and
B6C3F1 mice (lymphoma, heart, forestomach, lung,
liver, mammary gland, and ovary) (R. L. Melnick,
NIEHS; R. A. Miller, Battelle Pacific Northwest Labs)
at exposure levels of 1000 ppm for the rat and 625 ppm
for the mouse. In other experiments just completed,
multiple organ neoplasia and gonadal atrophy were ob-
served in mice exposed to concentrations as low as 62.5
ppm of 1,3-butadiene for 65 weeks; data for the 2-year
exposures are currently being evaluated and will be
made available later this year.
Research aimed at explaining the species differences
in organ sites of butadiene-induced carcinogenicity has
focused on the potential influence of an endogenous
retrovirus in B6C3F1 mice (R. D. Irons, Chemical In-
dustry Institute ofToxicology) and on pharmacokinetic
considerations (A. R. Dahl, Lovelace Biomedical and
Environmental Research Institute; R. J. Laib, Institut
furArbeitsphysiologie und der Universitat Dortmund).
A retrovirus involvement was suggested since the inci-
dence of thymic lymphomas was induced to a lesser
extent in NIH Swiss mice than in B6C3F1 mice that
were exposed to 1250 ppmbutadiene for 1 year, and the
endogenous ecotropic retrovirus recovered fromtissues
of B6C3F1 mice was not expressed in exposed NIH
Swiss mice. Inhalation pharmacokinetic studies have
shown that butadiene is metabolized more rapidly by
mice than rats and that reactive monoepoxide and di-
epoxide intermediates were produced in both species.
DNAandhemoglobinadductshavebeendetectedinrats
and mice exposed to radiolabeled butadiene. Hemo-
globin adduct measurements may be useful in monitor-
ing workplace exposures to butadiene. 1,3-Butadiene
was genotoxic to mouse but not rat bone marrow cells
(M. D. Shelby, NIEHS; G. T. Arce, E. I. du Pont de
Nemours & Co.). This gas did notinduce malfornations
inrats ormice; however, developmentaltoxicityinmice
was indicated because ofthe decrease in fetal weight of
male mice where the dams were exposed to 40 ppm or
higher (R. E. Morrissey, NIEHS).
Complementary toxicologic studies on isoprene, the
2-methylanalogof1,3-butadiene, areimportantbecause
of the close structural similarities between these two
chemicals. Isoprene, used predominantly in the manu-
factureofsyntheticelastomers, isalsogenotoxictobone
marrow cells ofmice (M. D. Shelby, NIEHS). Isoprene
maybemetabolized to areactive andmutagenic diepox-
ideintermediate (P. G. Gervasi, InstitutodiMutagenesi
e Differenziamento) and produces nonneoplastic lesions
in the testis, nasal cavity, and forestomach that are
similartothose causedby 1,3-butadiene (R. L. Melnick,
NIEHS). The rate ofmetabolism ofisoprene appears to
be greater in mice than in rats (H. Peter, Institut fur
Arbeitsphysiologie und der Universitat Dortmund).
Further studies are inprogress todeterminethe effects
oflong-term exposure to isoprene and to compare these
results with those found for 1,3-butadiene.
A most important element ofthe symposium was the
update of the three epidemiological cohort mortality
studies of workers exposed to 1,3-butadiene (R. A.
Lemen, NIOSH; B. J. Divine, Texaco, Inc.; G. Mata-
noski, Johns Hopkins University). In all three studies,
theratesofoverallworkermortalityaswellasmo'rtality
for all cancers were lower than those of the general
population. However, the finding of excess mortalities
from lymphatic and hematopoietic cancers among sub-
groups of workers occupationally exposed to 1,3-buta-
diene (e.g., standardizedmortalityratios were 500% for
lymphopoietic cancers and 660% for leukemia in black
productionworkers)indicatesthatthereisnowevidence
forthecarcinogenicity ofbutadieneinhumans(G. Mata-
noski, Johns Hopkins University; P. J. Landrigan,
Mount Sinai School of Medicine). Conversely, another
reported that the evidence for human carcinogenicity is
inadequate (M. G. Ott, A. D. Little, Inc.). Availabledata
priortothismeetingdidnotprovideevidenceofcarcino-
genicity ofbutadiene in humans. As with most epidemi-
ologic studies, these studies lack adequate quantitative
exposure data. A case control study of the styrene-
butadiene rubber industry is in prQgress to further
evaluate the possible relationship between butadiene
exposure and lymphopoietic cancer in humans (J. F.
Acquavella, Exxon Biomedical Sciences). The risk as-
sessmentsfor 1,3-butadiene, based oninhalationstudies
in rats and mice, demonstrate that there is significant
predictedriskassociatedwiththeoccupationalexposure
to 100 ppm butadiene over a working lifetme (E. A.
Grossman, OSHA;) orwith airexposure forpopulations
living near industrial sources ofbutadiene emissions (I.
L. Cote, EPA).
Further experimental research on 1,3-butadiene is
needed to elucidate the mechanism of 1,3-butadiene-
induced carcinogenicity, to resolve further the possible
effectofaretrovirusinthisprocess, andtorelatespecies
differences in target concentrations ofreactive metab-
olites to differences in organ sites of neoplasia. Alter-
native metabolic pathways, includingthose fordetoxifi-
cation, should also be explored further (M. G. Bird,
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Exxon Biomedical Sciences). Future work in epidemi-
ology should include updates ofthe existing studies and
quantitative measurements to assess more fully the
association between mortality outcome and exposure to
1,3-butadiene (M. G. Ott, Arthur D. Little, Inc.). The
additional research on 1,3-butadiene will be helpful in
clarifying the carcinogenic relationship ofthis chemical
between animals and humans.
For the success of this symposium on 1,3-butadiene, special ap-
preciation isextended to David Rall, Director, NIEHS; WilliamTess-
mer, Managing Director, IISRP; Symposium Organizers (R. L. Mel-
nick, NIEHS and M. G. Bird, Exxon Biomedical Sciences); Session
Chairs(L. Beliczky,J. Huff, M. Wooder, E. Loeser, R. Scala, D. Hoel,
and J. D. Millar); all of the speakers; the attendees; and the co-
sponsors.
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